Ignite Creation Date:
2025-12-24 @ 5:47 PM
Ignite Modification Date:
2026-01-04 @ 4:55 AM
Study NCT ID:
NCT01660568
Status:
COMPLETED
Last Update Posted:
2013-02-13
First Post:
2012-08-06
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Gemcitabine in NK/T Cell Lymphoma
Sponsor:
Samsung Medical Center
Organization:
Study Overview
Official Title:
Gemcitabine in Pretreated/Refractory NK/T Cell Lymphoma
Status:
COMPLETED
Status Verified Date:
2012-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
We retrospectively review patients with refractory or relapsed ENKL who received a gemcitabine-containing regimen
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: